Futility and harm bounds for overall survival monitoring2 hours ago
Introduction | Regulatory context: FDA guidance on OS monitoring in oncology | Design framework overview | Design with non-binding bounds (test.type = 8) | Spending function specification | Summary | Detailed boundary table | Interpreting the boundaries | Boundary crossing probabilities | Visualization | Z-value boundaries | Approximate treatment effect at boundaries | Conditional power at boundaries | Spending function plot | B-values at boundaries | Design with binding bounds (test.type = 7) | Comparing binding and non-binding | Efficacy bounds at alternate $\alpha$ levels | Practical considerations | Choice of spending functions | Interpreting the harm bound | Harm bound capping | When to use test.type = 7 vs. test.type = 8 | Binding and non-binding harm monitoring | Adjusting the boundaries | References
